Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.58 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | KDM1A | O60341 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | XDH | P47989 | 1/20 | 0.58 |
| ▸ | IPMK | Q8NFU5 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | PLG | P00747 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8306291 | 0.97 | CYP1B1 (0.68) | CYP1B1CYP1A1CYP1A2IP6K2MEN1 | |
| SCHEMBL4575595 | 0.94 | CYP1B1 (0.73) | CYP1B1CYP1A1CYP1A2IP6K2MEN1 | |
| SCHEMBL8305042 | 0.94 | CYP1B1 (0.58) | CYP1B1CYP1A1CYP1A2IP6K2MEN1 | |
| SCHEMBL8304881 | 0.93 | CYP1B1 (0.68) | CYP1B1CYP1A1CYP1A2IP6K2MEN1 | |
| SCHEMBL4575622 | 0.93 | CYP1B1 (0.68) | CYP1B1CYP1A1CYP1A2IP6K2MEN1 | |
| SCHEMBL4575616 | 0.93 | CYP1B1 (0.68) | CYP1B1CYP1A1CYP1A2IP6K2MEN1 | |
| SCHEMBL8431111 | 0.93 | CYP1B1 (0.57) | CYP1B1CYP1A1CYP1A2IP6K2MEN1 | |
| SCHEMBL8304688 | 0.90 | CYP1B1 (0.56) | CYP1B1CYP1A1CYP1A2IP6K2MEN1 | |
| SCHEMBL4575135 | 0.89 | CYP1B1 (0.56) | CYP1B1CYP1A1CYP1A2IP6K2MEN1 | |
| SCHEMBL8309779 | 0.89 | ABCB1 (0.56) | CYP1B1CYP1A1CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0709383-B1 | Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1999-12-15 | — | — | EP | claimed |
| US-5629339-A | CHRONIC VENOUS INSUFFICIENCY | ADIR ET COMPAGNIE (FR) | 1997-05-13 | — | — | US | claimed |
| EP-0709383-A1 | Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1996-05-01 | — | — | EP | claimed |
| US-20080176934-A1 | Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies | LES LABORATOIRES SERVIER (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176934-A1 | Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies | LES LABORATOIRES SERVIER (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176934-A1 | Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies | LES LABORATOIRES SERVIER (FR) | 2008-07-24 | — | — | US | disclosed |
| EP-0709383-B1 | Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1999-12-15 | — | — | EP | disclosed |
| US-5629339-A | CHRONIC VENOUS INSUFFICIENCY | ADIR ET COMPAGNIE (FR) | 1997-05-13 | — | — | US | disclosed |
| EP-0709383-A1 | Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176934-A1 | Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies | ADAMTS13, ADAMTS1, SERPINC1 | CYP1B1 340/4885CYP1A1 545/4885CYP1A2 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.